Senior Director, Rare Epilepsy HCP & Payer Marketing

Do you want to join a team where the mission is meaningful, the challenges are complex, and you can directly see the results of your hard work? Lundbeck is a global biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Lundbeck employees are inspired and driven by our purpose to advance brain health and transform lives. Join us on our journey of growth!

Bexicaserin is an investigational therapy that has not been approved by the Food and Drug Administration (FDA) for use in Developmental and Epileptic Encephalopathies (DEEs) or any indication. Additional research and information are needed to fully evaluate its safety and efficacy.

The Senior Director, Rare Epilepsy HCP & Payer Marketing, through practical and visionary leadership, is responsible for leading the overall Neuro Rare Epilepsy HCP marketing strategy and developing integrated commercialization initiatives to support successful launch readiness, market shaping, and long‑term business growth. This role leads HCP personal, payer‑related, non‑personal, and omnichannel marketing efforts across the Rare Epilepsy portfolio, with a strong focus on disease‑state education, customer engagement, and improving the patient and caregiver experience within rare and specialty neurological diseases.

The Senior Director works closely with Medical Affairs, Market Access, Patient Support Services, Sales Leadership, Patient Advocacy, Analytics, and Commercial Operations to deliver integrated HCP educational experiences and customer engagement strategies that foster understanding of the patient journey and encourage informed clinical decision‑making within Neuro Rare disease states. This individual also partners with Market Access leadership to formulate payer strategy and approach.

This leader drives high‑impact HCP and payer engagement strategies grounded in a deep understanding of the patient journey, specialty/rare access landscape, referral pathways, and the evolving Rare Epilepsy ecosystem.

• Lead the development and execution of US Rare Epilepsy HCP marketing strategy in partnership with key cross‑functional leaders. Responsible for Onfi™, Sabril™, and bexicaserin (pipeline product).
• Drive launch readiness, market shaping, disease‑state education, and customer engagement initiatives across the Rare Epilepsy portfolio.
• Ensure alignment of HCP brand positioning, customer segmentation, messaging, and business objectives across the organization.
• Partner with Market Access to create and refine payer strategy and approaches.
• Develop HCP and payer‑focused strategies informed by the patient, caregiver, and provider journey.
• Lead HCP educational initiatives that support disease awareness, diagnosis, and appropriate treatment adoption.
• Oversee integrated go‑to‑market planning, omnichannel engagement, and field readiness initiatives.
• Leverage market insights, analytics, competitive intelligence, and field feedback to optimize strategy and execution.
• Partner with global colleagues to align marketing activities as appropriate.
• Partner closely with Medical Affairs, Market Access, Sales, Patient Advocacy, and Analytics to support successful commercialization and long‑term growth.
• Build relationships with key opinion leaders (KOLs), centers of excellence, advocacy organizations, payers, and specialty providers.

• Oversee HCP personal, payer‑related, non‑personal, and omnichannel marketing strategy and execution across the portfolio.
• Drive integrated customer engagement strategies tailored to specialty neurology and rare epilepsy audiences, including Centers of Excellence (COEs).
• Support payer education, referral pathways, and customer access initiatives in partnership with Market Access teams.
• Apply customer insights and analytics to optimize HCP engagement and business performance.
• Ensure alignment and execution across cross‑functional teams, agency partners, and key stakeholders.
• S…